Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA.
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
BMC Med Genomics. 2020 May 14;13(1):69. doi: 10.1186/s12920-020-0729-7.
Chromothripsis is an event of genomic instability leading to complex chromosomal alterations in cancer. Frequent long-range chromatin interactions between transcription factors (TFs) and targets may promote extensive translocations and copy-number alterations in proximal contact regions through inappropriate DNA stitching. Although studies have proposed models to explain the initiation of chromothripsis, few discussed how TFs influence this process for tumor progression.
This study focused on genomic alterations in amplification associated regions within chromosome 17. Inter-/intra-chromosomal rearrangements were analyzed using whole genome sequencing data of breast tumors in the Cancer Genome Atlas (TCGA) cohort. Common ERα binding sites were defined based on MCF-7, T47D, and MDA-MB-134 breast cancer cell lines using univariate K-means clustering methods. Nanopore sequencing technology was applied to validate frequent rearrangements detected between ATC loci on 17q23 and an ERα hub on 20q13. The efficacy of pharmacological inhibition of a potentially druggable target gene on 17q23 was evaluated using breast cancer cell lines and patient-derived circulating breast tumor cells.
There are five adjoining regions from 17q11.1 to 17q24.1 being hotspots of chromothripsis. Inter-/intra-chromosomal rearrangements of these regions occurred more frequently in ERα-positive tumors than in ERα-negative tumors. In addition, the locations of the rearrangements were often mapped within or close to dense ERα binding sites localized on these five 17q regions or other chromosomes. This chromothriptic event was linked to concordant upregulation of 96 loci that predominantly regulate cell-cycle machineries in advanced luminal tumors. Genome-editing analysis confirmed that an ERα hub localized on 20q13 coordinately regulates a subset of these loci localized on 17q23 through long-range chromosome interactions. One of these loci, Tousled Like Kinase 2 (TLK2) known to participate in DNA damage checkpoint control, is an actionable target using phenothiazine antipsychotics (PTZs). The antiproliferative effect of PTZs was prominent in high TLK2-expressing cells, compared to low expressing cells.
This study demonstrates a new approach for identifying tumorigenic drivers from genomic regions highly susceptible to ERα-related chromothripsis. We found a group of luminal breast tumors displaying 17q-related chromothripsis for which antipsychotics can be repurposed as treatment adjuncts.
染色体重排是导致癌症中复杂染色体改变的基因组不稳定性事件。转录因子 (TFs) 和靶标之间频繁的长距离染色质相互作用可能会通过不适当的 DNA 拼接促进近端接触区域的广泛易位和拷贝数改变。尽管研究提出了一些模型来解释染色体重排的发生,但很少有研究讨论 TFs 如何影响肿瘤进展过程中的这一过程。
本研究专注于染色体 17 上与扩增相关区域的基因组改变。使用癌症基因组图谱 (TCGA) 队列中的乳腺癌全基因组测序数据分析了染色体内/间重排。基于 MCF-7、T47D 和 MDA-MB-134 乳腺癌细胞系,使用单变量 K-均值聚类方法定义了常见的 ERα 结合位点。应用纳米孔测序技术验证了在 17q23 上的 ATC 位点和在 20q13 上的 ERα 中心之间检测到的频繁重排。使用乳腺癌细胞系和患者来源的循环乳腺癌细胞评估了对 17q23 上潜在可药物靶基因的药理抑制的效果。
从 17q11.1 到 17q24.1 有五个毗邻区域是染色体重排的热点。这些区域的染色体内/间重排在 ERα 阳性肿瘤中比在 ERα 阴性肿瘤中更为频繁。此外,重排的位置通常位于这些五个 17q 区域或其他染色体上定位的密集 ERα 结合位点内或附近。这种染色体重排事件与高级腔型肿瘤中 96 个主要调节细胞周期机制的基因的上调相一致。基因组编辑分析证实,位于 20q13 上的 ERα 中心通过长距离染色体相互作用协调调节位于 17q23 上的这些基因的子集。这些基因中的一个,已知参与 DNA 损伤检查点控制的 Tousled Like Kinase 2 (TLK2),是使用吩噻嗪类抗精神病药 (PTZs) 作为治疗辅助的可操作靶点。与低表达细胞相比,高表达 TLK2 的细胞中 PTZs 的抗增殖作用更为明显。
本研究提出了一种从易受 ERα 相关染色体重排影响的基因组区域中识别致癌驱动基因的新方法。我们发现了一组显示 17q 相关染色体重排的腔型乳腺癌,其中抗精神病药可被重新用作治疗辅助剂。